Intel stock spikes after report of possible US government stake
LOS ANGELES - Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage pharmaceutical company with a strong balance sheet showing more cash than debt, has received a grant of $876,000 from the U.S. Department of Defense to support research aimed at combating resistance to lung cancer treatment. InvestingPro analysis shows the company maintains a healthy current ratio of 2.84, indicating solid short-term financial stability. The grant will fund a study at Cedars-Sinai Medical Center, specifically in Dr. Neil Bhowmick’s laboratory, to identify biomarkers for patients with non-small cell lung carcinoma who have developed resistance to the drug osimertinib.
The funded research is expected to facilitate early detection of resistance development in these patients, potentially leading to more timely and effective treatment interventions. This could improve overall survival rates and quality of life for those affected by this form of lung cancer, which is common among non-smokers.
According to Kairos Pharma CEO John Yu, M.D., the grant is a recognition of the scientific foundation of the company’s current Phase 1 trial involving lung cancer patients treated with ENV105 in combination with osimertinib. While the stock has experienced a significant decline, trading near its 52-week low of $0.85, analysts maintain optimistic price targets ranging from $4 to $12 per share. For deeper insights into KAPA’s potential, InvestingPro subscribers have access to over 30 additional financial metrics and analysis tools. He expressed that such peer-reviewed support highlights the potential of ENV105 to provide effective therapy for lung cancer patients.
ENV105 is an antibody that targets CD105, a protein linked to drug resistance and immune suppression in cancer. The company’s strategy involves using ENV105 to reverse drug resistance by targeting CD105, thereby restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is currently also in a Phase 2 clinical trial for castrate-resistant prostate cancer.
The press release from Kairos Pharma emphasizes that the DoD grant will help advance their clinical trials while managing costs. With a market capitalization of $12.43 million and current trading levels suggesting potential undervaluation according to InvestingPro Fair Value metrics, investors seeking comprehensive analysis can access detailed financial health scores and growth projections through the Pro platform. The company’s statement also includes forward-looking statements that involve risks and uncertainties, and actual results may differ from those projected.
This news is based on a press release statement from Kairos Pharma, Ltd.
In other recent news, Kairos Pharma has announced significant developments in its clinical trials and drug pipeline. The company has completed the safety lead-in phase of its Phase 2 trial for ENV105, a treatment for metastatic castration-resistant prostate cancer, and has moved to the randomized phase. Kairos Pharma also reported promising findings in a peer-reviewed study that could address resistance to EGFR-targeted therapies in non-small cell lung cancer (NSCLC). The study highlighted ENV105’s potential to enhance the efficacy of existing treatments by targeting the CD105 protein. Additionally, the company shared positive preclinical data on two investigational compounds, KROS 101 and KROS 401, which showed potential in combating tumor growth and enhancing immune response in cancer models.
H.C. Wainwright initiated coverage on Kairos Pharma with a Buy rating and a $12 price target, citing the potential of its oncology pipeline to address cancer resistance. The firm emphasized the importance of upcoming data from clinical trials as key milestones for the company. In its recent Letter to Shareholders, Kairos outlined achievements from 2024, including its IPO and collaborations to develop biomarker panels for ENV105. Looking ahead to 2025, Kairos plans to continue its clinical trials for ENV105 in prostate and lung cancers, with initial safety data expected in the first half of the year. The company remains focused on advancing its oncology therapeutics portfolio, aiming to provide long-term value for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.